Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 -386.22M
June 30, 2026 16.67M
March 31, 2026 69.96M
December 31, 2025 5.097M
September 30, 2025 0.3261M
June 30, 2025 9.114M
March 31, 2025 12.18M
December 31, 2024 -6.886M
September 30, 2024 71.89M
June 30, 2024 -19.78M
March 31, 2024 -7.316M
December 31, 2023 1.404M
September 30, 2023 -7.183M
June 30, 2023 -61.38M
March 31, 2023 -138.22M
December 31, 2022 -20.42M
September 30, 2022 -29.87M
June 30, 2022 -21.92M
March 31, 2022 20.57M
December 31, 2021 -1.992M
Date Value
September 30, 2021 40.10M
June 30, 2021 28.86M
March 31, 2021 76.85M
December 31, 2020 43.30M
September 30, 2020 34.60M
June 30, 2020 82.16M
March 31, 2020 -204.77M
December 31, 2019 -88.80M
September 30, 2019 -22.03M
June 30, 2019 63.10M
March 31, 2019 22.00M
December 31, 2018 -35.12M
September 30, 2018 -12.78M
June 30, 2018 -71.66M
March 31, 2018 12.54M
December 31, 2017 -15.49M
September 30, 2017 -2.190M
June 30, 2017 -20.45M
March 31, 2017 6.589M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. -10.22B
Faeth Therapeutics, Inc. 0.175M
ACADIA Pharmaceuticals, Inc. -86.15M
Alnylam Pharmaceuticals, Inc. -311.74M
Anika Therapeutics, Inc. -1.756M